309 Retroperitoneal lymph node recurrence of epithelial ovarian cancer: prognostic factors and treatment outcome

Objectives To compare the treatment outcome and survival of patients with recurrence in retroperitoneal lymph nodes versus women with intraperitoneal recurrence. Methods This retrospective cohort study included patients treated for ovarian, tubal and primary peritoneal cancer in Wolfson Medical Center during the years 2000–2015. We classified three groups according to the site of recurrence: intraperitoneal only, retroperitoneal lymph nodes only, and both. Response to treatment was assessed by the RECIST criteria. Progression free survival (PFS), post-recurrence survival (PRS) and overall survival (OS) were estimated with the Kaplan-Meier method and compared with Log-rank test. The association between clinical variables and survival was established by Cox proportional hazards model. Results Out of 135 patients in our cohort, 66 were diagnosed with intraperitoneal recurrence, 30 with retroperitoneal lymph node recurrence and 39 with combined recurrence. The clinical, pathological and surgical characteristics were similar among all groups, besides CA-125, which was significantly lower in the retroperitoneal recurrence group at diagnosis, end of treatment and recurrence. The median follow up period was 45.8 months. OS and PRS were significantly higher in the retroperitoneal recurrence group compared to the intraperitoneal and combined recurrence groups. (OS – 93.07 vs. 47.9 and 41.7 months, respectively, p=0.000, PRS – 68.57 vs. 29.67 and 19.7 months, respectively, p=0.000). In multivariate analysis, retroperitoneal recurrence was found to be an independent prognostic factor for survival. Conclusions The site of recurrence has significant prognostic value regarding PRS and OS. Patients with retroperitoneal lymph node recurrence only, have a favorable prognosis with estimated survival longer than 5 years.